Clinical Trials Logo

Filter by:
NCT ID: NCT04642287 Not yet recruiting - Skin Cancer Clinical Trials

Immunotherapy After Transplantation for Skin Cancer Prevention in Organ Transplant Recipients

Start date: January 2026
Phase: Phase 2
Study type: Interventional

This clinical trial aims to investigate the efficacy of Calcipotriol ointment combined with 5-FU cream in Organ Transplant Recipients (OTRs) to determine if it can stimulate the immune cells against actinic keratoses precancerous skin lesions after transplantation and prevent cutaneous squamous cell carcinoma (SCC) in long-term.

NCT ID: NCT04641117 Not yet recruiting - Clinical trials for Exercise Training and Sarcopenia

Time Efficient Exercise to Reverse Sarcopenia and Improve Cardio-metabolic Health

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

Participants will be 60-80 y men and women who vary their physical activity (steps/day) while their lipid metabolism is studied (n=24). Thereafter, another group (n=60) will perform 6 months of exercise training focused on developing maximal cycling power, during which their changes in muscle mass and practical function will be carefully measured.

NCT ID: NCT04640675 Not yet recruiting - Clinical trials for Osteoarthritis Pain of the Knee

A 12-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Osteoarthritis Pain of the Knee

Start date: December 2020
Phase: Phase 3
Study type: Interventional

A 12-week, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 study to Evaluate the Efficacy and Safety of HP-5000 in Subjects with Osteoarthritis (OA) Pain of the Knee

NCT ID: NCT04636073 Not yet recruiting - Clinical trials for Aortic Valve Stenosis

The Leaflex™ Early Feasibility Study

Start date: December 2024
Phase: N/A
Study type: Interventional

A prospective, multicenter, single-arm, early feasibility study aimed to assess safety and performance of the Leaflex™ Performer in the treatment of patients with symptomatic, severe aortic stenosis. Subjects will be seen at pre- and post procedure, discharge, 30 days and at 3, 6, 9 and 12 months post procedure.

NCT ID: NCT04630847 Not yet recruiting - Clinical trials for Autism Spectrum Disorder

Familial Fecal Microbiota Transplant for the Treatment of Subjects With Autism Spectrum Disorders

Start date: May 2022
Phase: Phase 1
Study type: Interventional

This is an open-label clinical trial to evaluate the benefits of familial fecal microbiota transplant following a 6-week treatment with Vancomycin in minor and adult subjects with ASD for treatment of social deficits and language delays.

NCT ID: NCT04628507 Not yet recruiting - Infertility, Female Clinical Trials

Cell Free Preimplantation Genetic Testing

Start date: June 11, 2024
Phase:
Study type: Observational

This study aims to develop preimplantation genetic testing methods from embryo culture media (cell free). Genetic testing of culture media will be compared to conventional methods based on embryo biopsies.

NCT ID: NCT04620512 Not yet recruiting - Clinical trials for Osteoarthritis, Knee

Cannabinoid Interactions With Central and Peripheral Pain Mechanisms in Osteoarthritis of the Knee

Start date: January 2021
Phase: Phase 2
Study type: Interventional

This clinical trial is being done to better understand how daily treatment with tetrahydrocannabinol (THC), cannabidiol (CBD), or the combination of CBD plus THC affects knee osteoarthritis pain and other related symptoms. Consented participants will have a screening period and visit (up to 30 days to treatment start). If participants pass the screening phase, they will be randomly assigned to take one of the investigational study drugs. For this study, participants will not know when or if they are taking CBD, THC, THC plus CBD, and when or if taking placebo. Clinical pain will be assessed at multiple times throughout the study, and eligibility will be re-assessed at two weeks into the treatment period. It is possible that subjects will not be able to participate in the study after two weeks of treatment.The treatment period will take approximately 16 weeks and then a follow-up period for approximately 2 weeks. In addition to treatment, participants will have clinical assessments, blood draws, questionnaires, daily pain diaries, sensory testing, as well as have functional connectivity magnetic resonance imaging (fcMRI). This studies primary hypothesis is that CBD alone will exert a peripheral anti-inflammatory effect shown through decreases in circulating levels of Interleukin-6 (IL-6), THC alone will modify central nervous system (CNS) pain processing via decreased insula to Default Mode Network (DMN) connectivity, and CBD plus THC will do both.

NCT ID: NCT04620278 Not yet recruiting - Cancer Clinical Trials

Genetic Investigation of Cancer Predisposition

Start date: October 2024
Phase:
Study type: Observational [Patient Registry]

Clinical information and samples (blood, saliva, and tumor) will be collected from patients with multiple cancers and/or a family history of cancer as well as from affected and unaffected relatives; samples will be systematically sequenced and evaluated for candidate driver mutations.

NCT ID: NCT04616001 Not yet recruiting - Covid19 Clinical Trials

IVIG in Patients With Severe COVID-19 Requiring Mechanical Ventilation

Start date: November 1, 2020
Phase: Phase 4
Study type: Interventional

The purpose of this Pilot Study is to establish a hypothesis of whether or not intravenous immunoglobulin (IVIG) may impact the hospital length of stay, if started within 48 of mechanical ventilation in patients infected with SARS-CoV-2 virus.

NCT ID: NCT04614623 Not yet recruiting - Type1diabetes Clinical Trials

Defining the Role of Management Factors in Outcome Disparity in Pediatric T1D

Start date: November 1, 2020
Phase: N/A
Study type: Interventional

Type 1 diabetes (T1D), is associated with considerable risk of morbidity and mortality due to chronic hyperglycemia. Despite innovations in management, pediatric patients of African ancestry (AA) have been found to have persistently higher mean blood glucose (MBG) than European ancestry (EA) patients. The investigators hypothesize that an intervention using advanced insulin delivery technology together with home management will sustainably improve MBG to levels comparable to EA patients without increasing hypoglycemia. The investigators will first perform a small "field trial" of the intervention in African American patients having T1D, with 8.5<HbA1c<12% aged 10-17 years. The primary intervention approach will use a combination of an advanced hybrid closed loop (AHCL) pump + enhanced home video management conferencing with study CDE nurse coordinator. Information gained in the "field trial" will be used to more specifically tailor the intervention in a randomized trial. In the second part , the investigators will conduct a randomized trial of the study intervention in participants with the same clinical features as the field trial for a six month pilot period. Participants will be randomized into one of four groups. The special intervention group (AHCL+conferencing) group will be compared with a group using patient's current insulin management+followup, vs AHCL+without conferencing, vs patient's standard insulin management+conferencing. The investigators will compare HbA1c, MBG, time in glycemic range, ability to adhere with home management, satisfaction with management procedures between the groups.